Yesterday, December 19th 2022, in a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive top-line results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis.
Positive Topline Results from Pivotal MAESTRO-NASH Trial of Resmetirom
Madrigal’s leadership intends to file for resmetirom’s accelerated approval with the FDA in the first half of 2023. If approved, the drug may become the first NASH medication introduced to market, depending on the outcome and timing of Intercept Pharmaceuticals’ refiling of obeticholic acid.
To recognize this special occasion, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the enthusiasm, synergy and implications surrounding the news. Alongside regular Surfers Jörn Schattenberg, Louise Campbell and Roger Green are friends of the podcast, Michael Betel, Donna Cryer, Scott Friedman, Kris Kowdley, Mazen Noureddin and Rachel Zayas. This is an unmissable, full house discussion which surveys what is primed to be a momentous breakthrough for the field. Surf on to hear what is to be a memorable episode.